Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Chronic Heart Failure

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 42 articles:
HTML format



Single Articles


    July 2021
  1. BROWN E, Heerspink HJL, Cuthbertson DJ, Wilding JPH, et al
    SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
    Lancet. 2021;398:262-276.
    PubMed     Abstract available


    May 2021

  2. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available


    February 2021
  3. LANGLEY RE, Gilbert DC, Duong T, Clarke NW, et al
    Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.
    Lancet. 2021;397:581-591.
    PubMed     Abstract available


    January 2021
  4. VADUGANATHAN M, Fonarow GC, McMurray JJV, Solomon SD, et al
    Considering dose in pharmacological therapies for heart failure - Authors' reply.
    Lancet. 2021;397:275.
    PubMed    


  5. SEEDAT Z, Itty K
    Considering dose in pharmacological therapies for heart failure.
    Lancet. 2021;397:274-275.
    PubMed    


    November 2020
  6. PONIKOWSKI P, Kirwan BA, Anker SD, McDonagh T, et al
    Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32339.
    PubMed     Abstract available


    August 2020
  7. ZANNAD F, Ferreira JP, Pocock SJ, Anker SD, et al
    SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Lancet. 2020 Aug 28. pii: S0140-6736(20)31824.
    PubMed     Abstract available


  8. BRAININ M, Sliwa K
    WSO and WHF joint position statement on population-wide prevention strategies.
    Lancet. 2020;396:533-534.
    PubMed    


  9. MACLAREN G
    In sepsis-induced heart failure, extracorporeal membrane oxygenation can provide support.
    Lancet. 2020;396:515-517.
    PubMed    


    May 2020
  10. PSOTKA MA, Teerlink JR
    Assessing the lifetime benefit of heart failure therapies.
    Lancet. 2020 May 21. pii: S0140-6736(20)30929.
    PubMed    


  11. VADUGANATHAN M, Claggett BL, Jhund PS, Cunningham JW, et al
    Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials.
    Lancet. 2020 May 21. pii: S0140-6736(20)30748.
    PubMed     Abstract available


    October 2019
  12. SUCHARD MA, Schuemie MJ, Krumholz HM, You SC, et al
    Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
    Lancet. 2019 Oct 24. pii: S0140-6736(19)32317.
    PubMed     Abstract available


    September 2019
  13. HAUSENLOY DJ, Kharbanda RK, Moller UK, Ramlall M, et al
    Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.
    Lancet. 2019 Sep 6. pii: S0140-6736(19)32039.
    PubMed     Abstract available


    August 2019
  14. SANTEMA BT, Ouwerkerk W, Tromp J, Sama IE, et al
    Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.
    Lancet. 2019 Aug 22. pii: S0140-6736(19)31792.
    PubMed     Abstract available


  15. WHITLEY HP, Smith WD
    Sex-based differences in medications for heart failure.
    Lancet. 2019 Aug 22. pii: S0140-6736(19)31812.
    PubMed    


    July 2019
  16. HALLIDAY BP, Cleland JGF, Prasad SK
    When can heart failure treatment be stopped safely? - Authors' reply.
    Lancet. 2019;394:217-218.
    PubMed    


  17. HA T, Korczyk D, Ng ACT, Wang WYS, et al
    When can heart failure treatment be stopped safely?
    Lancet. 2019;394:217.
    PubMed    


  18. THIBODEAU JT, Drazner MH
    When can heart failure treatment be stopped safely?
    Lancet. 2019;394:216-217.
    PubMed    


    March 2019
  19. BAX JJ, Di Carli M, Narula J, Delgado V, et al
    Multimodality imaging in ischaemic heart failure.
    Lancet. 2019;393:1056-1070.
    PubMed     Abstract available


  20. NORMAND C, Kaye DM, Povsic TJ, Dickstein K, et al
    Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology.
    Lancet. 2019;393:1045-1055.
    PubMed     Abstract available


  21. ROSSIGNOL P, Hernandez AF, Solomon SD, Zannad F, et al
    Heart failure drug treatment.
    Lancet. 2019;393:1034-1044.
    PubMed     Abstract available


    February 2019
  22. BARGE-CABALLERO G, Gargallo-Fernandez P, Barge-Caballero E, Crespo-Leiro MG, et al
    Popeye's sign, heart disease, and amyloidosis.
    Lancet. 2019;393:e32.
    PubMed    


    November 2018
  23. WILCOX J, Yancy CW
    Stopping medication for heart failure with improved ejection fraction.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32825.
    PubMed    


  24. HALLIDAY BP, Wassall R, Lota AS, Khalique Z, et al
    Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial.
    Lancet. 2018 Nov 9. pii: S0140-6736(18)32484.
    PubMed     Abstract available


    August 2018
  25. CLELAND JFG, Clark RA
    Telehealth: delivering high-quality care for heart failure.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31995.
    PubMed    


  26. KOEHLER F, Koehler K, Deckwart O, Prescher S, et al
    Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial.
    Lancet. 2018 Aug 24. pii: S0140-6736(18)31880.
    PubMed     Abstract available


  27. THE LANCET
    Heart failure: the need for improved treatment and care.
    Lancet. 2018;392:451.
    PubMed    


    June 2018
  28. PATEL T, Tesfaldet B, Chowdhury I, Kettermann A, et al
    Endpoints in diabetes cardiovascular outcome trials.
    Lancet. 2018;391:2412.
    PubMed    


    March 2018
  29. DZIADZKO V, Clavel MA, Dziadzko M, Medina-Inojosa JR, et al
    Outcome and undertreatment of mitral regurgitation: a community cohort study.
    Lancet. 2018;391:960-969.
    PubMed     Abstract available


  30. MCKELLAR S
    The promissory nature of artificial hearts.
    Lancet. 2018;391:930-931.
    PubMed    


    November 2017
  31. THE LANCET
    Heart failure in an ageing population.
    Lancet. 2017 Nov 22. pii: S0140-6736(17)33039.
    PubMed    


  32. CONRAD N, Judge A, Tran J, Mohseni H, et al
    Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.
    Lancet. 2017 Nov 21. pii: S0140-6736(17)32520.
    PubMed     Abstract available


  33. ZANNAD F
    Rising incidence of heart failure demands action.
    Lancet. 2017 Nov 21. pii: S0140-6736(17)32873.
    PubMed    


    April 2017
  34. METRA M, Teerlink JR
    Heart failure.
    Lancet. 2017 Apr 28. pii: S0140-6736(17)31071.
    PubMed     Abstract available


    January 2017
  35. LEAUTE-LABREZE C, Harper JI, Hoeger PH
    Infantile haemangioma.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)00645.
    PubMed     Abstract available


    December 2016
  36. SLIWA K
    The heart of Africa: succeeding against the odds.
    Lancet. 2016;388:e28-e36.
    PubMed     Abstract available


  37. PACKER M, McMurray JJ
    Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure.
    Lancet. 2016 Dec 2. pii: S0140-6736(16)30969.
    PubMed     Abstract available


    November 2016
  38. TEERLINK JR, Felker GM, McMurray JJ, Solomon SD, et al
    Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial.
    Lancet. 2016 Nov 30. pii: S0140-6736(16)32049.
    PubMed     Abstract available


  39. RODES-CABAU J, Taramasso M, O'Gara PT
    Diagnosis and treatment of tricuspid valve disease: current and future perspectives.
    Lancet. 2016;388:2431-2442.
    PubMed     Abstract available


    August 2016
  40. PICCINI JP, Fauchier L
    Rhythm control in atrial fibrillation.
    Lancet. 2016;388:829-840.
    PubMed     Abstract available


  41. VAN GELDER IC, Rienstra M, Crijns HJ, Olshansky B, et al
    Rate control in atrial fibrillation.
    Lancet. 2016;388:818-828.
    PubMed     Abstract available


    February 2016
  42. BLACHER J, Levy BI, Mourad JJ, Safar ME, et al
    From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century.
    Lancet. 2016 Feb 5. pii: S0140-6736(16)00002.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: